section
Finance
Markets, money, and the business of the world. Read-only — these stories don't post to Matrix.
375 stories archived
Apple's Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
Apple shares near record highs on strong iPhone Duo foldable demand, but a Loop Capital downgrade and nearly 40 times earnings valuation raise questions ahead of its Nov. 2 earnings report.
Netflix Is Making Big Changes, But Can It Fix What's Really Hurting Growth?
Netflix beat Q3 EPS estimates but shares fell after weak Q4 revenue guidance and slowing growth, prompting UBS, Piper Sandler and Rosenblatt to trim price targets.
Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Solid Power is commissioning its MOBIUS continuous manufacturing line in Colorado, boosting capacity as it targets a South Korean joint venture and holds a strong balance sheet despite a stock decline.
Off-Price, High-Yield: Why Ross Stores Is Defying the Retail Slump
UBS upgraded Ross Stores with a Street-high $315 target, citing revenue growth potential, but a near-28 P/E ratio and recent insider selling raise valuation concerns.
Whirlpool's Stock Collapse Raises a Bigger Question About Its Recovery Potential
Whirlpool stock fell after weak Q3 revenue and guidance, but improving free cash flow, debt reduction, and heavy institutional buying suggest the housing-driven downturn may be overdone.
Analysts Turn Bullish on Meta Platforms Despite Post-Earnings Fall
After Meta's Q3 earnings beat, analysts raised price targets, citing bullish Muse AI agent revenue potential, despite the stock falling 7% and margins declining.
Approaching Earnings Season, Are Pure Play Quantum Stocks Still a Good Bet?
Ahead of earnings, IonQ and D-Wave show contrasting growth forecasts, while legacy firms IBM and Alphabet leverage infrastructure, funding, and quantum tech advances like Google's Willow processor.
Lockheed Martin's F-35 Deal Could Change How Wall Street Values the Stock
Morgan Stanley upgraded Lockheed Martin to Overweight and raised its price target to $835, citing a 10-year F-35 framework, record $292 billion backlog, and a 22nd straight annual dividend increase.
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.
Intel's $155 Price Target Raises a Bigger Question About Its Turnaround Potential
KeyBanc set a $155 price target on Intel after a 25% pullback, as server CPU shortages, an FCC regulatory waiver, and CEO insider buying support its Oct. 29 earnings outlook.
AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
AST SpaceMobile advances toward 2026 commercial service amid SpaceX spectrum competition, satellite launch delays, and shares hitting a new 52-week low.
GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
GXO Logistics is deploying Agility Robotics' humanoid robots via a RaaS model to cut labor costs, as rising short interest and institutional buying set up volatility ahead of Nov. 4 earnings.
A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
Deckers beat EPS estimates but missed on revenue and cut its FY2027 sales outlook for HOKA and UGG, sending DECK stock down 5%, even as margins expanded and buybacks continued.
Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
Verizon's mixed Q3 results show margin gains, record adjusted EBITDA, raised guidance, and strong free cash flow, supporting its dividend, buybacks, and multiyear recovery despite SpaceX spectrum concerns.
Mega and Large Investors Pull Back from Housing Market, Become Net Sellers, Small Investors Continue to Pile In
Who is the smart money, after the home-price explosion?
Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
Comfort Systems USA posted record Q3 revenue and backlog, but declining gross margins and vague 2027 guidance triggered a sharp sell-off amid broader AI trade concerns.
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.
5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
Teradyne, Grail, Kratos Defense, FormFactor and Fabrinet have pulled back despite strong growth, setting up potential entry points in robotics, quantum and AI.
Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Anthropic's IPO filing reveals $224.5 billion in non-cancelable compute deals with Amazon and Alphabet, highlighting NVIDIA and Broadcom as key beneficiaries of AI infrastructure spending.
Insiders Are Selling These 5 AI Stocks—Should You Worry?
Insiders at CoreWeave, Arista Networks, Dell, Snowflake and NVIDIA have been selling shares, but analyst ratings, institutional buying and fundamentals suggest the AI trade's outlook remains largely intact.
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.
3 Companies With Room to Pass on Costs to Manage Inflation
As inflation accelerates, WD-40, Balchem, and Interparfums show pricing power and sales resilience despite rising chemical, freight, and logistics costs pressuring margins.
Actively Managed ETFs Are Giving In to the Price War—To the Benefit of Investors
Low-fee active ETFs DFLV, DFAC, and USMC now rival passive funds on cost, but comparisons with Vanguard alternatives show mixed performance and liquidity trade-offs for investors.
Not All Tech Is Getting Crushed: 5 Names Holding Up Through the AI Sell-Off
While chip stocks slide, cybersecurity and software names like HACK, IGV, Microsoft, CrowdStrike, and Palantir hold near highs, suggesting a rotation within tech rather than a broad exit.